Marília Gabriella Alves Goulart Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marília Gabriella Alves Goulart Pereira has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Carla Speroni Ceron
Univ Fed Ouro Preto, Dept Biol Sci, Ouro Preto, MG, Brazil
2 shared publicationsAlessandra Oliveira Silva
Univ Fed Alfenas, Dept Food & Med, Alfenas, MG, Brazil
1 shared publication- Alessandra Oliveira Silva
Federal University of Alfenas, Alfenas, Minas Gerais, Brazil
1 shared publication - Ana Flávia da Silva Amorim
Department of Food and Drugs, Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Brazil
1 shared publication - Andrea Mollica Do Amarante Paffaro
Science Space, Museum and Archives System (SIMA), Federal University of Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil
1 shared publication - Bruno Mendes
Biomolecules Discovery Group, Universidad Regional Amazónica Ikiam, Km 7 Via Muyuna, Tena 150101, Ecuador
1 shared publication
Latest Publications
- Open Access
- 16 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3544
Molecular and Functional Alterations of P-Glycoprotein in a Genetic Model of Epilepsy: Insights from the Wistar Audiogenic Rat
Drug resistance remains a major challenge in epilepsy, and overexpression of ATP-binding cassette transporters, particularly P-glycoprotein (P-gp), at the blood–brain barrier (BBB) has been consistently implicated in limiting central nervous system drug exposure. Genetic experimental models suitable for investigating molecular regulation and functional alterations of P-gp in epilepsy remain scarce. This study evaluated P-gp expression and functional alterations in the Wistar Audiogenic Rat (WAR), a genetic model of epilepsy exhibiting phenotypic heterogeneity. WAR animals were classified into refractory epilepsy (WAR-RE) or temporal lobe epilepsy (WAR-TLE) phenotypes and compared with non-epileptic Wistar controls. Fexofenadine, a well-established in vivo P-gp probe substrate, was administered orally, and plasma pharmacokinetic parameters were determined. P-gp expression at the BBB was assessed by immunohistochemistry in hippocampal regions. WAR-RE animals exhibited significantly increased systemic exposure to fexofenadine, characterized by higher area under the curve and prolonged half-life, alongside reduced apparent clearance, compared with control animals (p < 0.05). In contrast, WAR-TLE animals showed greater interindividual variability without statistically significant differences. Immunohistochemical analysis revealed increased P-gp expression in hippocampal microvessels in both WAR phenotypes. These findings demonstrate that the WAR model displays molecular upregulation of P-gp at the BBB, accompanied by functional alterations in the disposition of a prototypical P-gp substrate. Although direct brain drug concentrations were not assessed, the integration of systemic pharmacokinetics with transporter expression supports the use of WAR as a genetic proof-of-concept model for studying P-gp regulation and transporter-mediated drug disposition in epilepsy. This model provides a valuable molecular framework for future investigations addressing transporter modulation and mechanisms underlying pharmacoresistance.
- 16 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3544
Open AccessMolecular and Functional Alterations of P-Glycoprotein in a Genetic Model of Epilepsy: Insights from the Wistar Audiogenic Rat
Drug resistance remains a major challenge in epilepsy, and overexpression of ATP-binding cassette transporters, particularly P-glycoprotein (P-gp), at the blood–brain barrier (BBB) has been consistently implicated in limiting central nervous system drug exposure. Genetic experimental models suitable for investigating molecular regulation and functional alterations of P-gp in epilepsy remain scarce. This study evaluated P-gp expression and functional alterations in the Wistar Audiogenic Rat (WAR), a genetic model of epilepsy exhibiting phenotypic heterogeneity. WAR animals were classified into refractory epilepsy (WAR-RE) or temporal lobe epilepsy (WAR-TLE) phenotypes and compared with non-epileptic Wistar controls. Fexofenadine, a well-established in vivo P-gp probe substrate, was administered orally, and plasma pharmacokinetic parameters were determined. P-gp expression at the BBB was assessed by immunohistochemistry in hippocampal regions. WAR-RE animals exhibited significantly increased systemic exposure to fexofenadine, characterized by higher area under the curve and prolonged half-life, alongside reduced apparent clearance, compared with control animals (p < 0.05). In contrast, WAR-TLE animals showed greater interindividual variability without statistically significant differences. Immunohistochemical analysis revealed increased P-gp expression in hippocampal microvessels in both WAR phenotypes. These findings demonstrate that the WAR model displays molecular upregulation of P-gp at the BBB, accompanied by functional alterations in the disposition of a prototypical P-gp substrate. Although direct brain drug concentrations were not assessed, the integration of systemic pharmacokinetics with transporter expression supports the use of WAR as a genetic proof-of-concept model for studying P-gp regulation and transporter-mediated drug disposition in epilepsy. This model provides a valuable molecular framework for future investigations addressing transporter modulation and mechanisms underlying pharmacoresistance.
- Open Access
- 29 May 2025
- Published by Universidade Federal do Pará in Amazônia: Revista de Educação em Ciências e Matemáticas
- Vol. 21 (46) , 180-195
Realidade virtual, realidade aumentada e mista na educação museal: uma análise cientométrica de tecnologias imersivas
O objetivo deste estudo foi investigar o impacto das tecnologias imersivas - realidade aumentada, virtual e mista na educação museal, destacando o impacto de autores, documentos e revistas. A análise incluiu 37 documentos indexados na Web of Science entre 2014 e 2024. Observou-se um crescimento anual de 17,46% nas publicações a partir de 2019, evidenciando o aumento de interesse no tema. As redes de colaboração (colaborações científicas) ainda são incipientes no Brasil, sugerindo a necessidade de fortalecer parcerias acadêmicas e ampliar o intercâmbio científico. As publicações analisadas apresentaram uma variação considerável no número de citações, com destaque para as áreas de museologia e tecnologias interativas. As revistas científicas mais influentes refletem uma difusão internacional e sinalizando um potencial das tecnologias imersivas.
- 29 May 2025
- Published by Universidade Federal do Pará in Amazônia: Revista de Educação em Ciências e Matemáticas
- Vol. 21 (46) , 180-195
Open AccessRealidade virtual, realidade aumentada e mista na educação museal: uma análise cientométrica de tecnologias imersivas
O objetivo deste estudo foi investigar o impacto das tecnologias imersivas - realidade aumentada, virtual e mista na educação museal, destacando o impacto de autores, documentos e revistas. A análise incluiu 37 documentos indexados na Web of Science entre 2014 e 2024. Observou-se um crescimento anual de 17,46% nas publicações a partir de 2019, evidenciando o aumento de interesse no tema. As redes de colaboração (colaborações científicas) ainda são incipientes no Brasil, sugerindo a necessidade de fortalecer parcerias acadêmicas e ampliar o intercâmbio científico. As publicações analisadas apresentaram uma variação considerável no número de citações, com destaque para as áreas de museologia e tecnologias interativas. As revistas científicas mais influentes refletem uma difusão internacional e sinalizando um potencial das tecnologias imersivas.
- 28 October 2024
- Published by Elsevier in Neuropeptides
- Vol. 108, 102480
Neuritogenesis and protective effects activated by Angiotensin 1–7 in astrocytes-neuron interaction
- 28 October 2024
- Published by Elsevier in Neuropeptides
- Vol. 108, 102480
Neuritogenesis and protective effects activated by Angiotensin 1–7 in astrocytes-neuron interaction
- Open Access
- 14 January 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (1) , 78
Antibacterial and Antiviral Properties of Chenopodin-Derived Synthetic Peptides
Antimicrobial peptides have been developed based on plant-derived molecular scaffolds for the treatment of infectious diseases. Chenopodin is an abundant seed storage protein in quinoa, an Andean plant with high nutritional and therapeutic properties. Here, we used computer- and physicochemical-based strategies and designed four peptides derived from the primary structure of Chenopodin. Two peptides reproduce natural fragments of 14 amino acids from Chenopodin, named Chen1 and Chen2, and two engineered peptides of the same length were designed based on the Chen1 sequence. The two amino acids of Chen1 containing amide side chains were replaced by arginine (ChenR) or tryptophan (ChenW) to generate engineered cationic and hydrophobic peptides. The evaluation of these 14-mer peptides on Staphylococcus aureus and Escherichia coli showed that Chen1 does not have antibacterial activity up to 512 µM against these strains, while other peptides exhibited antibacterial effects at lower concentrations. The chemical substitutions of glutamine and asparagine by amino acids with cationic or aromatic side chains significantly favoured their antibacterial effects. These peptides did not show significant hemolytic activity. The fluorescence microscopy analysis highlighted the membranolytic nature of Chenopodin-derived peptides. Using molecular dynamic simulations, we found that a pore is formed when multiple peptides are assembled in the membrane. Whereas, some of them form secondary structures when interacting with the membrane, allowing water translocations during the simulations. Finally, Chen2 and ChenR significantly reduced SARS-CoV-2 infection. These findings demonstrate that Chenopodin is a highly useful template for the design, engineering, and manufacturing of non-toxic, antibacterial, and antiviral peptides.
- 14 January 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (1) , 78
Open AccessAntibacterial and Antiviral Properties of Chenopodin-Derived Synthetic Peptides
Antimicrobial peptides have been developed based on plant-derived molecular scaffolds for the treatment of infectious diseases. Chenopodin is an abundant seed storage protein in quinoa, an Andean plant with high nutritional and therapeutic properties. Here, we used computer- and physicochemical-based strategies and designed four peptides derived from the primary structure of Chenopodin. Two peptides reproduce natural fragments of 14 amino acids from Chenopodin, named Chen1 and Chen2, and two engineered peptides of the same length were designed based on the Chen1 sequence. The two amino acids of Chen1 containing amide side chains were replaced by arginine (ChenR) or tryptophan (ChenW) to generate engineered cationic and hydrophobic peptides. The evaluation of these 14-mer peptides on Staphylococcus aureus and Escherichia coli showed that Chen1 does not have antibacterial activity up to 512 µM against these strains, while other peptides exhibited antibacterial effects at lower concentrations. The chemical substitutions of glutamine and asparagine by amino acids with cationic or aromatic side chains significantly favoured their antibacterial effects. These peptides did not show significant hemolytic activity. The fluorescence microscopy analysis highlighted the membranolytic nature of Chenopodin-derived peptides. Using molecular dynamic simulations, we found that a pore is formed when multiple peptides are assembled in the membrane. Whereas, some of them form secondary structures when interacting with the membrane, allowing water translocations during the simulations. Finally, Chen2 and ChenR significantly reduced SARS-CoV-2 infection. These findings demonstrate that Chenopodin is a highly useful template for the design, engineering, and manufacturing of non-toxic, antibacterial, and antiviral peptides.
- Open Access
- 15 July 2023
- Published by IP Innovative Publication Pvt Ltd in Journal of Pharmaceutical and Biological Sciences
- Vol. 11 (1) , 18-25
Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
- 15 July 2023
- Published by IP Innovative Publication Pvt Ltd in Journal of Pharmaceutical and Biological Sciences
- Vol. 11 (1) , 18-25
Open AccessTapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
- Open Access
- 23 December 2020
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14
Epilepsy Seizures in Spontaneously Hypertensive Rats After Acoustic Stimulation: Role of Renin–Angiotensin System
Hypertension is a common comorbidity observed in individuals with epilepsy. Growing evidence suggests that lower blood pressure is associated with reduced frequency and severity of seizures. In this study, we sought to investigate whether the renin–angiotensin system (RAS), which is a critical regulator of blood pressure, is involved in the pathogenesis of audiogenic epilepsy-related seizures in a hypertensive rat model. Spontaneously hypertensive rats (SHRs) were given RAS inhibitors, angiotensin-converting enzyme (ACE) inhibitor or angiotensin II type I receptor (AT1R) antagonist, for 7 days prior to inducing epileptic seizures by acoustic stimulation. After the pretreatment phase, blood pressure (BP) of SHRs normalized as expected, and there was no difference in systolic and diastolic BP between the pretreated SHRs and normotensive rat group (Wistar). Next, treated and untreated SHRs (a high BP control) were individually subjected to acoustic stimuli twice a day for 2 weeks. The severity of tonic–clonic seizures and the severity of temporal lobe epilepsy seizures (product of forebrain recruitment) were evaluated by the mesencephalic severity index (Rossetti et al. scale) and the limbic index (Racine’s scale), respectively. Seizures were observed in both untreated (a high BP control) SHRs and in SHRs treated with AT1R antagonist and ACE inhibitor. There was no statistical difference in the mesencephalic severity and limbic index between these groups. Our results demonstrate that SHRs present seizure susceptibility with acoustic stimulation. Moreover, although RAS inhibitors effectively reduce blood pressure in SHR, they do not prevent developing epileptic seizures upon acoustic stimulation in SHR. In conclusion, our study shows that RAS is an unlikely link between hypertension and susceptibility to epileptic seizures induced by acoustic stimulation in SHRs, which is in contrast with the anticonvulsant effect of losartan in other animal models of epilepsy.
- 23 December 2020
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14
Open AccessEpilepsy Seizures in Spontaneously Hypertensive Rats After Acoustic Stimulation: Role of Renin–Angiotensin System
Hypertension is a common comorbidity observed in individuals with epilepsy. Growing evidence suggests that lower blood pressure is associated with reduced frequency and severity of seizures. In this study, we sought to investigate whether the renin–angiotensin system (RAS), which is a critical regulator of blood pressure, is involved in the pathogenesis of audiogenic epilepsy-related seizures in a hypertensive rat model. Spontaneously hypertensive rats (SHRs) were given RAS inhibitors, angiotensin-converting enzyme (ACE) inhibitor or angiotensin II type I receptor (AT1R) antagonist, for 7 days prior to inducing epileptic seizures by acoustic stimulation. After the pretreatment phase, blood pressure (BP) of SHRs normalized as expected, and there was no difference in systolic and diastolic BP between the pretreated SHRs and normotensive rat group (Wistar). Next, treated and untreated SHRs (a high BP control) were individually subjected to acoustic stimuli twice a day for 2 weeks. The severity of tonic–clonic seizures and the severity of temporal lobe epilepsy seizures (product of forebrain recruitment) were evaluated by the mesencephalic severity index (Rossetti et al. scale) and the limbic index (Racine’s scale), respectively. Seizures were observed in both untreated (a high BP control) SHRs and in SHRs treated with AT1R antagonist and ACE inhibitor. There was no statistical difference in the mesencephalic severity and limbic index between these groups. Our results demonstrate that SHRs present seizure susceptibility with acoustic stimulation. Moreover, although RAS inhibitors effectively reduce blood pressure in SHR, they do not prevent developing epileptic seizures upon acoustic stimulation in SHR. In conclusion, our study shows that RAS is an unlikely link between hypertension and susceptibility to epileptic seizures induced by acoustic stimulation in SHRs, which is in contrast with the anticonvulsant effect of losartan in other animal models of epilepsy.